Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Amortization of Deferred Charges: 2020-2021

Historic Amortization of Deferred Charges for SAB Biotherapeutics (SABS) over the last 2 years, with Dec 2021 value amounting to $164,983.

  • SAB Biotherapeutics' Amortization of Deferred Charges fell 40.09% to $24,717 in Q3 2022 from the same period last year, while for Sep 2022 it was $138,939, marking a year-over-year change of. This contributed to the annual value of $164,983 for FY2021, which is 0.03% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Amortization of Deferred Charges stood at $164,983 for FY2021, which was down 0.03% from $165,036 recorded in FY2020.
  • Over the past 5 years, SAB Biotherapeutics' Amortization of Deferred Charges peaked at $165,036 during FY2020, and registered a low of $164,983 during FY2021.
  • Moreover, its 2-year median value for Amortization of Deferred Charges was $165,010 (2020), whereas its average is $165,010.
  • Data for SAB Biotherapeutics' Amortization of Deferred Charges shows a maximum YoY declined of 0.03% (in 2021) over the last 5 years.
  • Over the past 2 years, SAB Biotherapeutics' Amortization of Deferred Charges (Yearly) stood at $165,036 in 2020, then declined by 0.03% to $164,983 in 2021.